MedTrace Logo

Phase II Pharmacokinetics Study of CAM2038

NCT02710526 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2020-04-30

Study results available
· View outcomes & findings →

Summary

Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.

Conditions

Interventions

DRUG

CAM2038

Long-Acting Subcutaneous Injectable Depot of Buprenorphine

Sponsors & Collaborators

  • Braeburn Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • James Sullivan · Parkway Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-05-17
Completion
2017-07-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710526 on ClinicalTrials.gov